BLAINJECTIONINJECTABLEPriority Review
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMDELLTRA (tarlatamab-dlle) is a bispecific antibody (BSAB) approved by the FDA in May 2024 for hematologic malignancies. It is engineered to simultaneously engage two distinct targets on cancer cells and immune effector cells, bridging them to trigger targeted cell death. The drug represents a novel immunotherapy approach designed for patients with specific blood cancers.
Growth
Early-stage growth product with moderate competitive pressure (30/100); early-career opportunity to shape launch strategy and commercial infrastructure for a novel modality.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Started Jan 2027
430 enrolled
Limited Stage Small-Cell Lung Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Started Apr 2026
160 enrolled
Small Cell Lung Cancer
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Started Apr 2026
48 enrolled
Extensive Stage Lung Small Cell Cancer
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Started Nov 2025
70 enrolled
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Started Sep 2025
30 enrolled
MelanomaMedullary Thyroid CancerSinonasal Undifferentiated Carcinoma+8 more
Worked on IMDELLTRA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.